Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MTTP | P55157 | 12/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | APOB | P04114 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12082746 | 0.93 | MTTP (0.46) | KDM4EMTTPGAAALDH1A1LMNA | |
| SCHEMBL14511189 | 0.90 | KDM4E (0.48) | KDM4EMTTPGAAALDH1A1LMNA | |
| SCHEMBL12082755 | 0.90 | MTTP (0.55) | KDM4EMTTPGAAALDH1A1LMNA | |
| SCHEMBL14511118 | 0.89 | MTTP (0.52) | KDM4EMTTPGAAALDH1A1LMNA | |
| SCHEMBL12082647 | 0.89 | MTTP (0.50) | KDM4EMTTPGAAALDH1A1LMNA | |
| SCHEMBL12082736 | 0.89 | GAA (0.53) | KDM4EMTTPGAAALDH1A1LMNA | |
| SCHEMBL14511177 | 0.88 | KDM4E (0.46) | KDM4EMTTPGAAALDH1A1LMNA | |
| SCHEMBL12082658 | 0.88 | KDM4E (0.51) | KDM4EMTTPGAAALDH1A1LMNA | |
| SCHEMBL12174484 | 0.85 | MTTP (0.66) | MTTPNPY2R | |
| SCHEMBL14511168 | 0.85 | MTTP (0.48) | KDM4EMTTPGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258304-B2 | N-aryl piperidine substituted biphenylcarboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-04 | — | — | US | disclosed |
| US-8258304-B2 | N-aryl piperidine substituted biphenylcarboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-04 | — | — | US | disclosed |
| US-20090156623-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES | MEERPOEL LIEVEN | 2009-06-18 | — | — | US | disclosed |
| US-20090156623-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES | MEERPOEL LIEVEN | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156623-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES | LIPC, PNLIP, GPR119 | KDM4E 944/4885MTTP 98/4885GAA 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.